Marinus Pharmaceuticals I... (MRNS)
NASDAQ: MRNS
· Real-Time Price · USD
0.55
0.00 (0.00%)
At close: Feb 10, 2025, 3:59 PM
0.00% (1D)
| Bid | 0.55 |
| Market Cap | 30.37M |
| Revenue (ttm) | 31.47M |
| Net Income (ttm) | -140.49M |
| EPS (ttm) | -2.47 |
| PE Ratio (ttm) | -0.22267206477732793 |
| Forward PE | -2.62 |
| Analyst | Hold |
| Ask | 0.55 |
| Volume | 1,100,953 |
| Avg. Volume (20D) | 1,810,773 |
| Open | 0.55 |
| Previous Close | 0.55 |
| Day's Range | 0.55 - 0.55 |
| 52-Week Range | 0.22 - 10.50 |
| Beta | 1.26 |
About MRNS
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol MRNS
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for MRNS stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts7 months ago
+41.65%
Marinus Pharmaceuticals shares are trading higher ...
Unlock content with
Pro Subscription
9 months ago
-82.49%
Marinus Pharmaceuticals shares are trading lower after the company announced its Phase 3 TrustTSC trial of Oral Ganaxolone did not meet its primary endpoint.
7 months ago · businesswire.com
Immedica to Acquire Biopharmaceutical Company Marinus Pharmaceuticals, Inc.STOCKHOLM & RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #MarinusPharma--Immedica Pharma AB (Immedica), a leading global rare disease company, and Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceuti...